Close Menu

This story has been updated to include additional comments from Illumina CEO Francis deSouza and CMO Phil Febbo.

NEW YORK – Illumina is in the process of obtaining regulatory approval for a pan-cancer genomic profiling assay in the US and Europe, which will be central to several new partnerships with pharma and genetic testing companies.

The next-generation sequencing-based clinical assay is one of several announcements Illumina CEO Francis deSouza made today at the virtual JP Morgan Healthcare Conference.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.